The FDA has approved the first-ever Wegovy pill for weight loss, with the oral GLP-1 offering a 16.6% average weight reduction as a needle-free alternative.

On Monday evening, the Food and Drug Administration approved Novo Nordisk’s high-dose oral formulation of semaglutide for obesity. In clinical trials, people taking the pill lost substantially more weight than those taking a placebo. The drug is expected to be available to the public early next year.

The FDA approved a pill version of the GLP-1 receptor agonist semaglutide (Wegovy), making it the first oral GLP-1 agent indicated for weight loss, Novo Nordisk announced on Monday.